Table 1:
Cohort summary, n=30
| Baseline characteristics | N (%) | |
|---|---|---|
| Age (years) | ||
| ≤30 | 4 (13%) | |
| 31–40 | 4 (13%) | |
| 41–50 | 6 (20%) | |
| 51–60 | 4 (13%) | |
| 61–70 | 10 (33%) | |
| ≥71 | 2 (7%) | |
| Sex (%male) | 17 (57%) | |
| Underlying diagnosis | ||
| Lymphoma | 8 (27%) | |
| AML | 7 (23%) | |
| MDS/Myelofibrosis | 6 (20%) | |
| ALL | 5 (17%) | |
| CMMoL | 2 (7%) | |
| Other* | 2 (7%) | |
| Conditioning regimen | ||
| Myeloablative | 16 (53%) | |
| Reduced intensity | 9 (30%) | |
| Non-myeloablative | 5 (17%) | |
| Transplant source | ||
| Peripheral blood | 20 (67%) | |
| Bone marrow | 8 (27%) | |
| Double umbilical cord blood | 2 (7%) | |
| Type of donor | ||
| Autologous | 3 (10%) | |
| Allogeneic | 27 (90%) | |
| Matched related donor | 10 (37%) | |
| Matched unrelated donor | 14 (52%) | |
| Mismatched unrelated donor | 3 (11%) | |
| TPN within 30 days | 15 (50%) | |
| Antibiotics within 30 days** | 30 (100%) | |
| Fluoroquinolones | 26 (87%) | |
| Beta-lactams | 14 (47%) | |
| Carbapenems | 6 (20%) | |
| Vancomycin (IV) | 12 (40%) | |
| Bacteremia species, n=32 | 32 (100%) | |
| Gram-positive | Staphylococcus aureus | 8 (25%) |
| Methicillin-sensitive | 5 (63%) | |
| Methicillin-resistant | 3 (38%) | |
| Staphylococcus epidermidis | 4 (13%) | |
| Streptococcus mitis | 7 (22%) | |
| Enterococcus faecium | 2 (6%) | |
| Rothia mucilaginosa | 2 (6%) | |
| Gram-negative | Escherichia coli | 4 (13%) |
| Klebsiella spp. | 3 (9%) | |
| Klebsiella pneumoniae | 2 (67%) | |
| Klebsiella oxytoca | 1 (33%) | |
| Enterobacter cloacae | 1 (3%) | |
| Pseudomonas aeruginosa | 1 (3%) |
List of abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CMMoL, chronic myelomonocytic leukemia; MDS, myelodysplastic syndrome; TPN, total parenteral nutrition; IV, intravenous
*
Other=Paroxysmal nocturnal hemoglobinuria, testicular cancer
**
Select categories of antibiotics (antibiotics are not exclusive and do not add up to 100%)